Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) PT at $11.58

OptimizeRx Co. (NASDAQ:OPRX) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.42.

OPRX has been the topic of several recent research reports. JMP Securities lowered their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. B. Riley began coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 price target on the stock. William Blair reiterated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Stifel Nicolaus decreased their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, Barclays dropped their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th.

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC raised its stake in shares of OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the period. Janney Montgomery Scott LLC purchased a new stake in OptimizeRx in the third quarter valued at approximately $810,000. First Light Asset Management LLC lifted its stake in OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after purchasing an additional 89,377 shares in the last quarter. Bullseye Asset Management LLC lifted its stake in OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after purchasing an additional 76,458 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its position in shares of OptimizeRx by 42.9% during the third quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock worth $1,868,000 after buying an additional 72,672 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $4.20 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.07. The stock’s 50 day simple moving average is $6.54 and its 200-day simple moving average is $8.93. The company has a market cap of $76.95 million, a PE ratio of -3.16 and a beta of 1.32. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.